Analysts Set Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) PT at $6.64

Key Points

• Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) has received an average consensus recommendation of "Hold" from twelve brokerages, with target prices ranging from $2.00 to $10.00.
• The company's recent quarterly earnings report showed a loss of ($0.08) earnings per share, missing analysts' estimates, while revenue of $46.85 million declined by 26.9% year-over-year.
• Institutional investors increased their holdings in Maravai LifeSciences, with notable increases from 12 West Capital Management LP and Alyeska Investment Group L.P., indicating ongoing confidence from large investors.

Shares of Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI - Get Free Report) have earned an average rating of "Hold" from the twelve analysts that are currently covering the firm, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, seven have given a hold recommendation and four have assigned a buy recommendation to the company. The average 1-year price target among analysts that have covered the stock in the last year is $6.64.

A number of research firms have weighed in on MRVI. Robert W. Baird decreased their price objective on shares of Maravai LifeSciences from $3.00 to $2.00 and set a "neutral" rating for the company in a research report on Tuesday, May 13th. Craig Hallum decreased their price objective on shares of Maravai LifeSciences from $12.00 to $10.00 and set a "buy" rating for the company in a research report on Tuesday, May 13th.

Institutional Trading of Maravai LifeSciences

Several institutional investors have recently added to or reduced their stakes in MRVI. Callan Family Office LLC acquired a new stake in Maravai LifeSciences in the second quarter worth $25,000. Ethic Inc. acquired a new stake in Maravai LifeSciences in the second quarter worth $26,000. McAdam LLC acquired a new stake in Maravai LifeSciences in the first quarter worth $31,000. Sherbrooke Park Advisers LLC acquired a new stake in Maravai LifeSciences in the fourth quarter worth $78,000. Finally, EntryPoint Capital LLC acquired a new stake in Maravai LifeSciences in the first quarter worth $32,000. Institutional investors own 50.25% of the company's stock.

Maravai LifeSciences Stock Down 5.1%

Shares of MRVI traded down $0.12 during midday trading on Wednesday, reaching $2.22. 1,184,533 shares of the company were exchanged, compared to its average volume of 2,473,974. The stock has a 50-day moving average price of $2.40 and a 200-day moving average price of $2.81. The company has a market cap of $565.35 million, a price-to-earnings ratio of -1.95 and a beta of 0.28. Maravai LifeSciences has a 1-year low of $1.66 and a 1-year high of $9.95. The company has a current ratio of 5.96, a quick ratio of 5.17 and a debt-to-equity ratio of 0.60.

Maravai LifeSciences (NASDAQ:MRVI - Get Free Report) last posted its quarterly earnings data on Monday, May 12th. The company reported ($0.08) earnings per share for the quarter, missing analysts' consensus estimates of ($0.07) by ($0.01). The firm had revenue of $46.85 million during the quarter, compared to analysts' expectations of $44.01 million. Maravai LifeSciences had a negative net margin of 67.14% and a negative return on equity of 12.91%. Maravai LifeSciences's quarterly revenue was down 26.9% on a year-over-year basis. Research analysts expect that Maravai LifeSciences will post -0.24 earnings per share for the current year.

About Maravai LifeSciences

Maravai LifeSciences Holdings, Inc, a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species.